section name header

Pronunciation

zoe-NISS-a-mide

Classifications

Therapeutic Classification: anticonvulsants

Pharmacologic Classification: sulfonamides

Indications

REMS


Action

  • Raises the threshold for seizures and reduces duration of seizures probably by action on sodium and calcium channels.
Therapeutic effects:
  • Decreased frequency of partial seizures.

Pharmacokinetics

Absorption: Well absorbed following oral administration.

Distribution: Binds extensively to red blood cells.

Protein Binding: 40%.

Metabolism/Excretion: Mostly metabolized by the liver; 35% excreted unchanged in urine. Some metabolism occurs via CYP3A4 enzyme system.

Half-Life: 63 hr (plasma).

Time/Action Profile

(blood levels)
ROUTEONSETPEAKDURATION
POunknown2–6 hr24 hr



Requires 2 wk of dosing to achieve steady-state blood levels.

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CNS: SUICIDAL THOUGHTS, drowsiness, fatigue, agitation/irritability, depression, dizziness, psychomotor slowing, psychosis, weakness

EENT: amblyopia, tinnitus

Resp: cough, pharyngitis

GI: anorexia, nausea, vomiting

F and E: metabolic acidosis

GU: kidney stones

Derm: STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, oligohydrosis ( in children), rash

Metab: hyperthermia ( in children)

Neuro: abnormal gait, hyperasthesia, incoordination, tremor

Misc: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS)

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Zonegran

Pot. Nursing Diagnoses

Code

NDC Code